[Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer].

Abstract

A drug use investigation of nanoparticle albumin-bound paclitaxel was conducted based on conditions for approval. A total of 963 patients were enrolled in this study from September 24, 2010 to February 14, 2011. Twenty-nine patients were excluded, and a total of 934 patients were evaluated for determining the safety of nanoparticle albumin-bound paclitaxel. Adverse drug reactions were observed in 92.8%of the patients, and major adverse drug reactions included myelosuppression and peripheral sensory neuropathy, both of which are characteristic adverse reactions of paclitaxel treatment. Both adverse drug reactions were observed at a high frequency after the second course of treatment, resulting in these reactions being primary causes for discontinuation. Increase in the rates of continuous drug administration may be accomplished by carrying out laboratory tests and noting the medical history in order to prevent myelosuppression from becoming serious and to perform earlier countermeasures for peripheral sensory neuropathy, leading to improved therapeutic effects.

• Authors: Seigo Nakamura, Hiroji Iwata, Yuya Funato, Kunio Ito, Yoshinori Ito
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 4 Pg. 447-55 (Apr 2015) ISSN: 0385-0684 [Print] Japan
• PMID: 25963691 (Publication Type: English Abstract, Journal Article, Multicenter Study)

Chemical References

• 130-nm albumin-bound paclitaxel
• Albumins
• Antineoplastic Agents, Phytogenic
• Paclitaxel

Topics

• Adolescent
• Adult
• Aged
• Albumins (adverse effects, therapeutic use)
• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Disease Progression
• Drug Administration Schedule
• Female
• Humans
• Middle Aged
• Paclitaxel (adverse effects, therapeutic use)
• Young Adult